Antengene announced the latest Phase I/II clinical data for ATG-022 in treating gastric cancer with an ORR of 42.9%

Zhitong
2025.01.22 07:25

Antengene Corporation today announced that the latest data from the CLINCH study, which is evaluating ATG-022 for the treatment of advanced or metastatic gastric cancer patients in China and Australia, will be presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. ATG-022 is an antibody-drug conjugate targeting the tight junction protein CLDN18.2, which is a type of cell adhesion molecule. The U.S. Food and Drug Administration has granted ATG-022 two orphan drug designations for the treatment of gastric cancer and pancreatic cancer. Data from the ongoing CLINCH study indicate that ATG-022 has shown good clinical efficacy in gastric cancer patients with varying levels of CLDN18.2 expression. The efficacy demonstrated in gastric cancer populations with different CLDN18.2 expression levels suggests that ATG-022 has the potential to become a highly competitive drug

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.